Dexcom is expanding its portfolio of continuous glucose monitors (CGMs) with the launch of Stelo, balancing the needs of patients and payors to maximize the use of the technology, CEO Kevin Sayer explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sayer sits down with BI analyst Matt Henriksson for an in-depth interview about how G7, Dexcom’s flagship CGM, is capturing share in every market it’s in, how the launch of Stelo opens up CGM access to nearly 25 million Type 2 diabetes patients in the US and how any patient can order the new CGM without a prescription.

<p>Dexcom is expanding its portfolio of continuous glucose monitors (CGMs) with the launch of Stelo, balancing the needs of patients and payors to maximize the use of the technology, CEO Kevin Sayer explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sayer sits down with BI analyst Matt Henriksson for an in-depth interview about how G7, Dexcom’s flagship CGM, is capturing share in every market it’s in, how the launch of Stelo opens up CGM access to nearly 25 million Type 2 diabetes patients in the US and how any patient can order the new CGM without a prescription.</p>

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

<p>Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.</p>

Vanguards of Health Care by Bloomberg Intelligence

Dexcom's Stelo Expands CGMs to Non-Insulin Type 2

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/b84f29aa-b275-4f5c-95e4-b14800d7bfa2/transcript